<?xml version='1.0' encoding='utf-8'?>
<document id="12076689"><sentence text="Development and validation of a high-performance liquid chromatography-mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma."><entity charOffset="150-168" id="DDI-PubMed.12076689.s1.e0" text="dihydroartemisinin" /></sentence><sentence text="A sensitive and selective method is described for the determination of artemether and its active dihydroartemisinin metabolite in human plasma using artemisinin as internal standard"><entity charOffset="97-115" id="DDI-PubMed.12076689.s2.e0" text="dihydroartemisinin" /><entity charOffset="149-160" id="DDI-PubMed.12076689.s2.e1" text="artemisinin" /><pair ddi="false" e1="DDI-PubMed.12076689.s2.e0" e2="DDI-PubMed.12076689.s2.e0" /><pair ddi="false" e1="DDI-PubMed.12076689.s2.e0" e2="DDI-PubMed.12076689.s2.e1" /></sentence><sentence text=" The method consists of a liquid-liquid extraction with subsequent evaporation of the supernatant to dryness followed by the analysis of the reconstituted sample by liquid chromatography-mass spectrometry (LC-MS) in single ion monitoring mode using atmospheric pressure chemical ionization (APCI) as an interface" /><sentence text=" Chromatography was performed on a C(18) reversed-phase column using acetonitrile-glacial acetic acid 0" /><sentence text="1% (66:34) as a mobile phase" /><sentence text=" The method was fully validated over a concentration range of 5-200 ng/ml using 0" /><sentence text="5 ml of human plasma per assay" /><sentence text=" Stability assessment was also included" /><sentence text=" The method was applied to the quantification of artemether and its metabolite in human plasma of healthy volunteers participating in pharmacokinetic drug-drug interaction studies" /><sentence text="" /></document>